Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 2/2016

01-02-2016 | Headache (R. B. Halker, Section Editor)

Non-Invasive Neuromodulation for Headache Disorders

Authors: Shuhan Zhu, Michael J. Marmura

Published in: Current Neurology and Neuroscience Reports | Issue 2/2016

Login to get access

Abstract

Migraine and other chronic headache disorders are common and if inadequately treated, can lead to significant disability. The effectiveness of medications can be limited by side effects, drug interactions, and comorbid diseases necessitating alternative methods. Technological developments in the past 5 years have made it possible to use non-invasive methods of neuromodulation to treat primary headache disorders. This field includes technologies such as supraorbital transcutaneous stimulation (STS), transcranial magnetic stimulation (TMS), and non-invasive vagal nerve stimulation (nVNS). Existing trials show these modalities are safe and well tolerated and can be combined with standard pharmacotherapy. We review the technologies, biological rationales, and trials involving non-invasive neuromodulation for the treatment of primary headache disorders.
Literature
1.
Lipton R, Stewart W, Diamond S, Diamond M, Reed M. Prevalence and burden of migraine in the United States: data from the American migraine study II. Headache. 2001;41:646–57.CrossRefPubMed
2.
Hepp Z, Dodick D, Varon S, Gillard P, Hansen R, Devine E. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2014;35:478–88.CrossRefPubMed
3.
The international classification of headache disorders, 3rd edition (beta version). Cephalagia 2013;33:629-808.
4.
Manack A, Buse D, Lipton R. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15:70–8.CrossRefPubMed
5.
6.
Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz M. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59:652–61.CrossRefPubMed
7.
Schwedt T, Dodick D, Hentz J, Trentman T, Zimmerman R. Occipital nerve stimulation for chronic headache—long-term safety and efficacy. Cephalalgia. 2007;27:153–7.CrossRefPubMed
8.
Saper J, Dodick D, Silberstein S, McCarville S, Sun M, Goadsby P. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalagia. 2010;31:271–85.CrossRef
9.
Tsubokawa T, Katayama Y, Yamamoto T, Hirayama T, Koyama S. Chronic motor cortex stimulation in patients with thalamic pain. J Neurosurg. 1993;78:393–401.CrossRefPubMed
10.
Fontaine D, Lazorthes Y, Mertens P, et al. Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension. J Headache Pain. 2010;11:23–31.PubMedCentralCrossRefPubMed
11.
Schoenen J, Clemente LD, vanderheede M, et al. Hypothalamic stimulation in chronic cluster headache: a pilot study of efficacy and mode of action. Brain. 2005;128:940–7.CrossRefPubMed
12.
Coughlin A, Badura A, Fleisher T, Guck T. Multidisciplinary treatment of chronic pain patients: its efficacy in changing patient locus of control. Arch Phys Med Rehabil. 2000;81:739–40.CrossRefPubMed
13.
Lefaucheur J, Andre-Obadia N, Antal A, Ayache S, Baeken C, Benninger D. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation. Clin Neurophys. 2014;125:2150–206.CrossRef
14.
Narayana S, Papanicolaou A, McGregor A, Boop F, Wheless J. Clinical applications of transcranial magnetic stimulation in pediatric neurology. J Child Neurol. 2014;30:1111–24.CrossRefPubMed
15.
Solomon S, Guglielmo K. Treatment of headache by transcutaneous electrical stimulation. Headache. 1985;25:12–5.CrossRefPubMed
16.
Tayeb Z, Hafeez F, Shafiq Q. Successful treatment of nummular headache with TENS. Cephalalgia. 2008;28:897–8.CrossRefPubMed
17.
Cruccu G, Aziz T, Garcia-Larresa L, et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol. 2007;14:952–70.CrossRefPubMed
18.
Sluka K, Judge M, McColley M, Reveiz P, Taylor B. Low frequency TENS is less effective than high frequency TENS at reducing inflammtion-induced hyperalgesia in morphone-tolerant rats. Eur J Pain. 2000;4:185–93.CrossRefPubMed
19.••
Piquet M, Balestra C, Sava S, Schoenen J. Supraorbital transcutaneous neurostimulation has sedative effects in healthy subjects. BMC Neurol. 2011;11:135. This study showed the device to be safe for use in healthy volunteers with verum stimulation leading to mild sedative effects. PubMedCentralCrossRefPubMed
20.
Craig A. Spinal and trigeminal lamina I input to the locus coeruleus anterogradely labeled with phaseolus vulgaris leucoagglutinin (PHA-L) in the cat and the monkey. Brain Res. 1992;584:325–8.CrossRefPubMed
21.••
Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator. Neurology. 2013;80:697–704. Double-blind, RTC, sham-controlled study for STS as a migraine preventive. Significantly reduced headache days at three months of use though did not reduce headache severity. CrossRefPubMed
22.
Magis D, Sava S, D'Elia T, Schoenen J. Safety and patients’ satisfaction of transcutaneous supraorbital neuroStimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013;14:95.PubMedCentralCrossRefPubMed
23.
Anand S, Hotson J. Transcranial magnetic stimulation: neurophysiological applications and safety. Brain and Cogn. 2002;50:366–86.CrossRef
24.
Rossini P, Rossi S. Transcranial magnetic stimulation: diagnostic, therapeutic and research potential. Neurology. 2007;68:484–8.CrossRefPubMed
25.
Wasserman E. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial magnetic Stimulation, June 5–7, 1996. Electroencephalogr Clin Neurophysiol. 1997;108:1–16.CrossRef
26.
Dodick D, Schembri C, Helmuth M, Aurora S. Transcranial magnetic stimulation for migraine: a safety review. Headache. 2010;50:1153–63.CrossRefPubMed
27.••
Lipton R, Dodick D, Silberstein S, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurology. 2010;9:373–80. Double-blind, RTC, sham-controlled study for TMS as abortive migraine treatment. Treatment group more likely to be pain free at 372 h but no differences seen in abortive medication use.CrossRefPubMed
28.
Almaraz A, Dilli E, Dodick D. The effect of prophylactic medications on TMS for migraine aura. Headache Curr. 2010;50:1630–3.CrossRef
29.
Bhola R, Kinsella E, Giffin N, et al. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain. 2015;16:51.PubMedCentralCrossRef
30.
Sadler R, Purdy R, Rahey S. Vagal nerve stimulation aborts migraine in patient with intractable epilepsy. Cephalagia. 2002;22:482–4.CrossRef
31.
Hord E, Evans M, Mueed S, Adamolekun B, Naritoku D. The effect of vagus nerve stimulation on migraines. J Pain. 2003;4:530–4.CrossRefPubMed
32.
Mauskop A. Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalagia. 2005;25:82–6.CrossRef
33.
Cecchini A, Mea E, Tullo V, et al. Vagus nerve stimulation in drug-resistant daily chronic migraine with depression: preliminary data. Neurol Sci 2009;30.
34.
Kirchner A, Birklein F, Stefan H, Handwerker H. Left vagus nerve stimulation suppresses experimentally induced pain. Neurology. 2000;55:1167–71.CrossRefPubMed
35.
Bohotin C, Scholsem M, Multon S, Martin D, Bohotin V, Schoenen J. Vagus nerve stimulation in awake rats reduces formalin-induced nociceptive behaviour and fos-immunoreactivity in trigeminal nucleus caudalis. Pain. 2003;101:3–12.CrossRefPubMed
36.
Oshinsky M, Murphy A, Hekierski H, Cooper M, Simon B. Non-invasive vagus nerve stimulation as treatment for trigeminal allodynia. Pain. 2014;155:1037–42.PubMedCentralCrossRefPubMed
37.
Schachter S, Saper C. Progress in epilepsy research: vagus nerve stimulation. Epilepsia. 1998;39:677–86.CrossRefPubMed
38.
Ferrari GD, Crijns H, Borggrefe M, et al. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J. 2011;32:857–5.CrossRef
39.
Sjogren M, Hellstrom P, Jonsson M, Runngerstam M, Silander H, Ben-Menachem E. Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer’s disease: a pilot study. J Clin Psych. 2002;63:972–80.CrossRef
40.
Silberstein S. Non-invasive vagus nerve stimulation in the treatment of migraine headache. Presented at the 4th European Headache and Migraine Trust International Congress; September 20, 2014; Copenhagen, Denmark.
41.••
Silberstein S, Silva AD, Calhoun A, Grosberg B, Lipton R, Cady R. Non-invasive vagus nerve stimulation for chronic migraine prevention in a prospective, randomized, sham-controlled pilot study (the EVENT Study): report from the double-blind phase. Presented at the 56th Annual Scientific Meeting of the American Headache Society; June 2014; Los Angeles, California. Double-blind, RTC, sham-controlled study for nVNS as migraine preventive. Reduced number of migraine days with more benefits seen after multiple months of use.
42.
Silberstein S, Silva AD, Calhoun A, Grosberg B, Lipton R, Cady R. Non-invasive vagus nerve stimulation for chronic migraine prevention in a prospective, randomized, sham-controlled pilot Study (the EVENT Study): report from the open-label phase. Presented at the 56th Annual Scientific Meeting of the American Headache Society; June 2014; Los Angeles, California.
43.••
Gaul C, Diener H, Solbach K, et al. Non-invasive vagus nerve stimulation using gammaCore® for the prevention and acute treatment of chronic cluster headache: report from the randomised phase of the PREVA study. Presented at the 4th European Headache and Migraine Trust International Congress; September 18–21, 2014; Copenhagen, Denmark. RCT, open-label study for nVNS as abortive and preventive in chronic cluster. Cluster preventive and abortive. Reduced number of headache days after 2 weeks.
44.
Gaul C, Diener H, Solbach K, et al. Non-invasive vagus nerve stimulation using gammaCore for the prevention and acute treatment of chronic cluster headache: report from the open-label phase of the PREVA study. Presented at the 4th European Headache and Migraine Trust International Congress; September 18–21, 2014; Copenhagen, Denmark.
45.
Silberstein S, Mechtler L, Kudrow D, et al. Efficacy and safety outcomes of non-invasive vagus nerve stimulation for the acute treatment (ACT1) of cluster headache study. Presented at the 57th Annual Scientific Meeting of the American Headache Society; Jun 18–21, 2015; Washington DC.
46.
Nesbitt A, Martin J, Tompkins E, Ruttledge M, Goadsby P. Initial use of a novel noninvasive vagus nerve stimulator for cluster headache treatment. Neurology. 2015;84:1249–53.CrossRefPubMed
47.
Grazzi L, Padovan A, Barbanti P. Role of neurostimulation in migraine. Neurol Sci. 2015;36 Suppl 1:S121–3.CrossRef
48.
Goadsby P, Grosberg B, Mauskop A, Cady R, Simmons K. Effect of noninvasive vagus nerve stimulation on acute migraine: an open label pilot study. Cephalagia. 2014;34:986–93.CrossRef
49.
Rainero I, Martino PD, Rubino E, Vaula G, Gentile S, Pinessi L. Non-invasive vagal nerve stimulation for the treatment of headache attacks in patients with chronic migraine and medication-overuse headache. Neurology 2014;82:P1.262.
50.
Keskin E, Onur O, Keskin H, Gamus I, Kafali H, Turhan N. Transcutaneous electrical nerve stimulation improves low back pain during pregnancy. Gynecol Obstet Investig. 2012;74:76–83.CrossRef
51.
Husain M, Stegman D, Trevino K. Pregnancy and delivery while receiving vagus nerve stimulation for the treatment of major depression: a case report. Ann Gen Psych. 2005;4:1–7.CrossRef
Metadata
Title
Non-Invasive Neuromodulation for Headache Disorders
Authors
Shuhan Zhu
Michael J. Marmura
Publication date
01-02-2016
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 2/2016
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-015-0620-7

Other articles of this Issue 2/2016

Current Neurology and Neuroscience Reports 2/2016 Go to the issue

Critical Care (S A Mayer, Section Editor)

Intraoperative Targeted Temperature Management in Acute Brain and Spinal Cord Injury

Behavior (H. S. Kirshner, Section Editor)

Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias

Neurology of Systemic Diseases (J Biller, Section Editor)

Neurocutaneous Disorders for the Practicing Neurologist: a Focused Review

Epilepsy (C. W. Bazil, Section Editors)

Neurogenesis in the Hippocampus of Patients with Temporal Lobe Epilepsy

Infection (J Halperin, Section Editor)

Developments in Varicella Zoster Virus Vasculopathy

Neuro-oncology (L A Abrey, Section Editor)

Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma